CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that the U.S. Patent Office has granted patent number US 7,465,449, which broadly covers monoclonal antibodies to integrin avß6, including compositions related to its lead product, STX-100. This patent provides Stromedix with strong intellectual property protection for antibody-based therapeutics directed against avß6 through at least 2023.
